Ozempic, Mounjaro and Mental Health: Mood and Appetite

Food noise describes persistent thoughts or preoccupation about food that feel intrusive or burdensome. It is a developing research concept, not a psychiatric diagnosis. Researchers have proposed definitions and measurement tools, but ordinary hunger, meal planning and enjoyment of food should not be treated as symptoms by themselves. Evidence.

Some people taking semaglutide or tirzepatide report that food occupies less mental space. Reduced appetite, fewer cravings and relief from intrusive thoughts are related experiences, but they are not identical measurements. The effect varies and should not be used as a self-test of whether a medicine is working.

Emotional eating means eating in response to feelings such as stress or loneliness. Binge eating involves episodes with a sense of loss of control; a clinical diagnosis depends on the pattern, associated features and distress. These experiences can overlap, and a change in appetite does not settle the diagnosis.

The FDA’s January 2026 review did not find an increased risk of suicidal thoughts or behaviour, depression or related psychiatric adverse events across the evidence it assessed. It requested removal of the suicidality warning from the weight-management products that carried it. This is reassuring at population level, not a guarantee about every person. Evidence.

New low mood, agitation or loss of interest still deserves attention. Describe the timing, other medicines and the effect on daily life. A symptom beginning after an injection is a reason to investigate, not proof that the injection caused it. For persistent symptoms, see the guide to low mood and depression.

Anhedonia means reduced interest or pleasure. Emotional blunting is a broader sense that feelings are muted. Less interest in food while still enjoying other parts of life is different from losing interest in relationships, music, intimacy and activities you used to value.

A 2026 case series described three people with anhedonia-like symptoms during tirzepatide treatment. Symptoms improved after clinician-led changes, which sometimes included another treatment. The report raises a question; it cannot establish how often this happens, prove the mechanism or tell another patient what dose change to make. Evidence.

Large safety studies do not answer every question about subtle emotional changes. Equally, a few reports do not establish a common adverse effect. The useful response is to assess the person’s experience without automatically blaming the medicine or dismissing the symptom. The emotional-numbness guide explains related experiences.

There is no reliable order that identifies the cause for everyone. The medicine, another treatment, reduced intake, sleep and a mental or physical health condition may contribute together.

Food, fluids and physical symptoms. Tell the prescriber about repeated nausea, vomiting, skipped meals, weakness or dizziness. A review can assess whether intake is adequate and whether tests or dietary support are indicated. Fatigue alone does not diagnose an iron or vitamin deficiency.

Mood, sleep and daily functioning. Loss of pleasure, hopelessness, poor sleep or withdrawal from relationships deserve review. Do not wait for symptoms to become severe or for an arbitrary number of weeks before asking for help.

Eating and coping. If food previously helped with stress, loneliness or boredom, a change in eating may leave those difficulties more noticeable. That is one possible experience, not an explanation to impose on every person who feels flat.

The medication timeline. Record when the injection began, when symptoms appeared, dose changes made by the prescriber, other medicines and any missed doses. This helps assess a possible treatment effect without turning timing alone into proof.

• The medicine and formulation, start date, and prescribed changes
• Which feelings or activities changed, and how they affect your day
• Sleep, food and fluid intake, nausea, vomiting or constipation
• All psychiatric medicines, other prescriptions and supplements
• Any restriction, purging, loss-of-control eating or fear of food

A smaller appetite does not necessarily mean an eating disorder is better. Tell the treating team about any history of anorexia, bulimia, binge eating, purging, laxative misuse or compulsive exercise. Body size alone does not establish whether eating is safe or an eating disorder has resolved.

GLP-1 medicines are being studied for eating-related symptoms, but they are not a substitute for a full eating-disorder plan. NICE recommends psychological approaches for binge-eating disorder and advises against medication as its sole treatment. Regular eating, reducing restrictive cycles and addressing distress may matter even when weight changes. Evidence.

Seek review if eating becomes frightening, rules grow increasingly rigid, or you are unable to eat and drink enough. A clinician and, where appropriate, an eating-disorder team or dietitian can help distinguish treatment-related appetite change from harmful restriction.

Clinical trials suggest semaglutide can reduce some aspects of alcohol craving or consumption in selected populations. That is a developing treatment research area, not a reason to replace established alcohol-use care or assume an injection has resolved dependence. Evidence.

If you drink heavily or may be dependent, obtain medical advice before abruptly stopping. Alcohol withdrawal can be dangerous even when the urge to drink decreases. Evidence.

A change in sexual interest, motivation or another behaviour needs its own assessment. It should not automatically be attributed to a single “dopamine” explanation. Sleep, mood, nutrition, other medicines and relationships can be relevant; report the particular change you are experiencing.

A change in body size does not guarantee a change in body image or self-worth. Loose skin, comments from others, repeated checking or fear of regaining weight can remain distressing. You can ask for help with these experiences without having to be grateful for the weight loss first.

Discuss concerns if they occupy much of your day, lead to avoiding people or meals, or drive rigid restriction or compulsive exercise. The aim is to improve functioning and your relationship with your body, not simply to pursue a lower number.

Appetite can return and weight regain is common after stopping weight-management medication. In the STEP 1 extension, the semaglutide group regained about two thirds of its previous weight loss over the following year. That group average does not predict an individual outcome. Evidence.

Plan follow-up before treatment stops, including the medical reason for stopping, nutrition support, costs and access to ongoing care. Insurance coverage and out-of-pocket costs vary; do not assume another person’s arrangement will apply to you.

Returning appetite can feel unsettling, particularly after a period of relief from food preoccupation. Regain is not evidence of weak willpower. If emotional eating, restriction or fear of food returns, bring that into the treatment plan alongside weight and metabolic measures.

Not everyone taking a weight-management medicine needs a psychiatrist. A review may help with persistent low mood, loss of pleasure, eating difficulties, body-image distress, alcohol problems or concerns about psychiatric medicines.

If weight gain followed psychiatric treatment, the medication-related weight-gain guide covers the relevant options and monitoring. People taking lithium or clozapine need particular coordination between their clinicians.

Bring the treatment timeline and current prescriptions. The aim is to understand what changed and agree a plan with the clinician managing the medical treatment, rather than decide from a webpage that one medicine must be stopped.